<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font19 { font-size : 19; } .font23 { font-size : 23; } .font27 { font-size : 27; } .font29 { font-size : 29; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">(%) </span>
   <span class="font29">CVS </span>
   <span class="font27">patients </span>
   <span class="font23">[Link] </span>
   <span class="font19">response </span>
   <span class="font19">evidence </span>
   <span class="font17">vomiting </span>
   <span class="font17">treatment </span>
   <span class="font17">prophylactic </span>
   <span class="font17">reported </span>
   <span class="font17">studies </span>
   <span class="font17">therapy </span>
   <span class="font16">study </span>
   <span class="font15">(‐) </span>
   <span class="font15">abortive </span>
   <span class="font15">included </span>
   <span class="font15">months </span>
   <span class="font15">used </span>
   <span class="font15">episodes </span>
   <span class="font15">clinical </span>
   <span class="font15">LOW </span>
   <span class="font15">adults </span>
   <span class="font15">response: </span>
   <span class="font15">⨁◯◯◯ </span>
   <span class="font15">Observational </span>
   <span class="font14">Reduction </span>
   <span class="font14">effects </span>
   <span class="font14">duration </span>
   <span class="font14">patient </span>
   <span class="font14">reduction </span>
   <span class="font14">frequency </span>
   <span class="font14">pediatric </span>
   <span class="font14">Amitriptyline </span>
   <span class="font14">group </span>
   <span class="font14">study, </span>
   <span class="font14">IMPORTANT </span>
   <span class="font14">attacks </span>
   <span class="font14">improvement </span>
   <span class="font14">migraine </span>
   <span class="font14">follow‐up </span>
   <span class="font14">use </span>
   <span class="font13">outcomes </span>
   <span class="font13">review </span>
   <span class="font13">Baseline </span>
   <span class="font13">Prophylactic </span>
   <span class="font13">data </span>
   <span class="font13">number </span>
   <span class="font13">CVS. </span>
   <span class="font13">certainty </span>
   <span class="font13">Propranolol </span>
   <span class="font13">Complete </span>
   <span class="font13">cohort </span>
   <span class="font13">{border-style </span>
   <span class="font12">Table </span>
   <span class="font12">based </span>
   <span class="font12">complete </span>
   <span class="font12">criteria </span>
   <span class="font12">Abortive </span>
   <span class="font12">Cyclic </span>
   <span class="font12">Cyproheptadine </span>
   <span class="font12">medication </span>
   <span class="font12">px;} </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">CVS? </span>
   <span class="font12">episode </span>
   <span class="font12">nausea </span>
   <span class="font12">received </span>
   <span class="font12">symptoms </span>
   <span class="font12">Certainty </span>
   <span class="font12">adult </span>
   <span class="font12">adverse </span>
   <span class="font12">amitriptyline </span>
   <span class="font12">aprepitant </span>
   <span class="font12">cyclic </span>
   <span class="font12">events </span>
   <span class="font12">months) </span>
   <span class="font12">taking </span>
   <span class="font12">topiramate </span>
   <span class="font12">years </span>
   <span class="font12">(/) </span>
   <span class="font12">(follow‐up: </span>
   <span class="font12">Boles </span>
   <span class="font12">history </span>
   <span class="font12">retrospective </span>
   <span class="font12">syndrome </span>
   <span class="font12">(/, </span>
   <span class="font12">Amitriptyline: </span>
   <span class="font12">Retrospective </span>
   <span class="font12">Vomiting </span>
   <span class="font12">bias </span>
   <span class="font12">mitochondrial </span>
   <span class="font12">response. </span>
   <span class="font12">(no </span>
   <span class="font12">Coenzyme </span>
   <span class="font12">Syndrome </span>
   <span class="font12">[], </span>
   <span class="font12">children </span>
   <span class="font12">diagnosis </span>
   <span class="font12">effect </span>
   <span class="font12">partial </span>
   <span class="font12">patients. </span>
   <span class="font12">population </span>
   <span class="font12">severity </span>
   <span class="font12">significant </span>
   <span class="font11">&amp;gt; </span>
   <span class="font11">Hikita </span>
   <span class="font11">III </span>
   <span class="font11">Partial </span>
   <span class="font11">Pediatric </span>
   <span class="font11">Rome </span>
   <span class="font11">Year </span>
   <span class="font11">control </span>
   <span class="font11">inform </span>
   <span class="font11">low </span>
   <span class="font11">severe </span>
   <span class="font11">symptom </span>
   <span class="font11">Adverse </span>
   <span class="font11">Cyproheptadine: </span>
   <span class="font11">Department </span>
   <span class="font11">Patients </span>
   <span class="font11">Study </span>
   <span class="font11">USA </span>
   <span class="font11">conducted </span>
   <span class="font11">decreased </span>
   <span class="font11">estimate </span>
   <span class="font11">increased </span>
   <span class="font11">levetiracetam </span>
   <span class="font11">met </span>
   <span class="font11">moderate </span>
   <span class="font11">propranolol </span>
   <span class="font11">selection </span>
   <span class="font11">studies, </span>
   <span class="font11">systematic </span>
   <span class="font11">triptans </span>
   <span class="font11">year </span>
   <span class="font11">(//) </span>
   <span class="font11">(C) </span>
   <span class="font11">Adult </span>
   <span class="font11">CVS, </span>
   <span class="font11">GRADE </span>
   <span class="font11">Hejazi </span>
   <span class="font11">John </span>
   <span class="font11">Sumatriptan </span>
   <span class="font11">Topiramate </span>
   <span class="font11">University </span>
   <span class="font11">Wiley </span>
   <span class="font11">achieved </span>
   <span class="font11">chart </span>
   <span class="font11">decrease </span>
   <span class="font11">family </span>
   <span class="font11">observational </span>
   <span class="font11">therapy. </span>
   <span class="font11">(%). </span>
   <span class="font11">CRITICAL </span>
   <span class="font11">Division </span>
   <span class="font11">Duration </span>
   <span class="font11">Episode </span>
   <span class="font11">Ltd, </span>
   <span class="font11">Medical </span>
   <span class="font11">Medicine </span>
   <span class="font11">Number </span>
   <span class="font11">Resolution: </span>
   <span class="font11">Response </span>
   <span class="font11">Sons, </span>
   <span class="font11">design </span>
   <span class="font11">dose </span>
   <span class="font11">effective </span>
   <span class="font11">failed </span>
   <span class="font11">medications </span>
   <span class="font11">profile </span>
   <span class="font11">statistically </span>
   <span class="font11">topiramate, </span>
   <span class="font11">treated </span>
   <span class="font11">(.%) </span>
   <span class="font11">Adults </span>
   <span class="font11">CI) </span>
   <span class="font11">Good </span>
   <span class="font11">PICO </span>
   <span class="font11">Risk </span>
   <span class="font11">amitriptyline, </span>
   <span class="font11">discontinuation </span>
   <span class="font11">disease) </span>
   <span class="font11">effects: </span>
   <span class="font11">following </span>
   <span class="font11">higher </span>
   <span class="font11">imprecision </span>
   <span class="font11">inclusion </span>
   <span class="font11">leading </span>
   <span class="font11">management </span>
   <span class="font11">mg/kg </span>
   <span class="font11">mg/kg/day): </span>
   <span class="font11">poor </span>
   <span class="font11">published </span>
   <span class="font11">px; </span>
   <span class="font11">randomized </span>
   <span class="font11">range </span>
   <span class="font11">rated </span>
   <span class="font11">remission </span>
   <span class="font11">remission: </span>
   <span class="font11">review. </span>
   <span class="font11">subcutaneous </span>
   <span class="font11">subjects </span>
   <span class="font11">zonisamide </span>
   <span class="font11">{font-family </span>
   <span class="font11">(.‐) </span>
   <span class="font11">(‐.) </span>
   <span class="font11">Co‐Q </span>
   <span class="font11">Frequency </span>
   <span class="font11">Gastroenterology </span>
   <span class="font11">Importance </span>
   <span class="font11">Imprecision </span>
   <span class="font11">Inconsistency </span>
   <span class="font11">Indirectness </span>
   <span class="font11">Key </span>
   <span class="font11">L‐carnitine </span>
   <span class="font11">Outcomes </span>
   <span class="font11">Potential </span>
   <span class="font11">Quality </span>
   <span class="font11">School </span>
   <span class="font11">Sezer </span>
   <span class="font11">Treatment </span>
   <span class="font11">acute </span>
   <span class="font11">assessment </span>
   <span class="font11">baseline </span>
   <span class="font11">benefits/harms </span>
   <span class="font11">confusion, </span>
   <span class="font11">considerations </span>
   <span class="font11">defined </span>
   <span class="font11">difference </span>
   <span class="font11">efficacy </span>
   <span class="font11">font-size </span>
   <span class="font11">group. </span>
   <span class="font11">median </span>
   <span class="font11">message </span>
   <span class="font11">mild </span>
   <span class="font11">outcome </span>
   <span class="font11">prior </span>
   <span class="font11">resolved </span>
   <span class="font11">response" </span>
   <span class="font11">risk </span>
   <span class="font11">sample </span>
   <span class="font11">search </span>
   <span class="font11">small </span>
   <span class="font11">studies. </span>
   <span class="font11">supplements </span>
   <span class="font11">symptoms. </span>
   <span class="font10">&amp;lt;% </span>
   <span class="font10">(days): </span>
   <span class="font10">(median </span>
   <span class="font10">.%), </span>
   <span class="font10">Association </span>
   <span class="font10">Cochrane </span>
   <span class="font10">Co‐enzyme </span>
   <span class="font10">Cristofori </span>
   <span class="font10">Kumar </span>
   <span class="font10">L‐Carnitine </span>
   <span class="font10">Mean </span>
   <span class="font10">Medication </span>
   <span class="font10">age </span>
   <span class="font10">agents </span>
   <span class="font10">available </span>
   <span class="font10">bias, </span>
   <span class="font10">concern </span>
   <span class="font10">concomitant </span>
   <span class="font10">developed </span>
   <span class="font10">discontinued </span>
   <span class="font10">dosage </span>
   <span class="font10">double; </span>
   <span class="font10">frequency, </span>
   <span class="font10">guideline </span>
   <span class="font10">improvement, </span>
   <span class="font10">improvement: </span>
   <span class="font10">individuals </span>
   <span class="font10">intensity </span>
   <span class="font10">interviews </span>
   <span class="font10">measured </span>
   <span class="font10">months. </span>
   <span class="font10">noted </span>
   <span class="font10">patients, </span>
   <span class="font10">population, </span>
   <span class="font10">possible </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">provided </span>
   <span class="font10">questions </span>
   <span class="font10">significantly </span>
   <span class="font10">sumatriptan </span>
   <span class="font10">tricyclic </span>
   <span class="font10">visits </span>
   <span class="font10">weight </span>
   <span class="font10">%). </span>
   <span class="font10">&amp;gt;/= </span>
   <span class="font10">/(%) </span>
   <span class="font10">Center </span>
   <span class="font10">Clouse </span>
   <span class="font10">Derry </span>
   <span class="font10">Maximum </span>
   <span class="font10">Neurogastroenterol </span>
   <span class="font10">Ondansetron </span>
   <span class="font10">REPORTED </span>
   <span class="font10">Severe </span>
   <span class="font10">TCAs </span>
   <span class="font10">TCAs, </span>
   <span class="font10">Valproic </span>
   <span class="font10">Wisconsin </span>
   <span class="font10">accompanying </span>
   <span class="font10">acid </span>
   <span class="font10">and/or </span>
   <span class="font10">antidepressants </span>
   <span class="font10">antiepileptic </span>
   <span class="font10">articles </span>
   <span class="font10">bias. </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">change </span>
   <span class="font10">concerns </span>
   <span class="font10">daily </span>
   <span class="font10">depression, </span>
   <span class="font10">different </span>
   <span class="font10">dizziness </span>
   <span class="font10">drugs </span>
   <span class="font10">duration, </span>
   <span class="font10">episodes) </span>
   <span class="font10">episodes; </span>
   <span class="font10">estimates </span>
   <span class="font10">events, </span>
   <span class="font10">fewer </span>
   <span class="font10">focused </span>
   <span class="font10">framework </span>
   <span class="font10">given </span>
   <span class="font10">headache </span>
   <span class="font10">headache, </span>
   <span class="font10">hospitalizations </span>
   <span class="font10">indirectness </span>
   <span class="font10">kg, </span>
   <span class="font10">lack </span>
   <span class="font10">literature </span>
   <span class="font10">medical </span>
   <span class="font10">mg) </span>
   <span class="font10">nasal </span>
   <span class="font10">numbers </span>
   <span class="font10">period </span>
   <span class="font10">practice </span>
   <span class="font10">presented </span>
   <span class="font10">quality </span>
   <span class="font10">rates </span>
   <span class="font10">recommendations </span>
   <span class="font10">regimen </span>
   <span class="font10">response, </span>
   <span class="font10">reviews </span>
   <span class="font10">said </span>
   <span class="font10">scale: </span>
   <span class="font10">seen </span>
   <span class="font10">solid; </span>
   <span class="font10">subject </span>
   <span class="font10">summary </span>
   <span class="font10">switched </span>
   <span class="font10">syndrome: </span>
   <span class="font10">therapies </span>
   <span class="font10">treatments </span>
   <span class="font10">trials </span>
   <span class="font10">using </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">%), </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">(Dosages </span>
   <span class="font10">(days) </span>
   <span class="font10">(defined </span>
   <span class="font10">(migraine‐associated </span>
   <span class="font10">(the </span>
   <span class="font10">Abortive: </span>
   <span class="font10">Absolute </span>
   <span class="font10">Badihian </span>
   <span class="font10">Cross‐sectional </span>
   <span class="font10">Data </span>
   <span class="font10">Dr. </span>
   <span class="font10">Effect </span>
   <span class="font10">Effective </span>
   <span class="font10">Gastroenterol </span>
   <span class="font10">Gastroenterol. </span>
   <span class="font10">Given </span>
   <span class="font10">Headache </span>
   <span class="font10">Hospital </span>
   <span class="font10">International </span>
   <span class="font10">Lee </span>
   <span class="font10">Likert </span>
   <span class="font10">L‐carnitine, </span>
   <span class="font10">L‐carnitine: </span>
   <span class="font10">Management </span>
   <span class="font10">Median </span>
   <span class="font10">Mild </span>
   <span class="font10">Moderate </span>
   <span class="font10">Motil. </span>
   <span class="font10">NASPGHAN </span>
   <span class="font10">Namin </span>
   <span class="font10">Neurol. </span>
   <span class="font10">New </span>
   <span class="font10">Phenobarbital </span>
   <span class="font10">Primary </span>
   <span class="font10">Propranolol: </span>
   <span class="font10">RCTs </span>
   <span class="font10">Randomized </span>
   <span class="font10">Relative </span>
   <span class="font10">Scale </span>
   <span class="font10">Sharaf </span>
   <span class="font10">Stanford </span>
   <span class="font10">Systematic </span>
   <span class="font10">TCA </span>
   <span class="font10">Tricyclic </span>
   <span class="font10">adolescents </span>
   <span class="font10">analysis </span>
   <span class="font10">appetite </span>
   <span class="font10">attack </span>
   <span class="font10">attendance: </span>
   <span class="font10">bold </span>
   <span class="font10">care </span>
   <span class="font10">case </span>
   <span class="font10">change) </span>
   <span class="font10">characteristics </span>
   <span class="font10">completely </span>
   <span class="font10">concentration/memory, </span>
   <span class="font10">consensus </span>
   <span class="font10">courier; </span>
   <span class="font10">created. </span>
   <span class="font10">deemed </span>
   <span class="font10">described </span>
   <span class="font10">did </span>
   <span class="font10">difficulty </span>
   <span class="font10">dizziness, </span>
   <span class="font10">dose, </span>
   <span class="font10">doses </span>
   <span class="font10">effect. </span>
   <span class="font10">em; </span>
   <span class="font10">episodes/year </span>
   <span class="font10">episodes/year: </span>
   <span class="font10">events. </span>
   <span class="font10">explicitly </span>
   <span class="font10">group: </span>
   <span class="font10">hallucinations </span>
   <span class="font10">hospital </span>
   <span class="font10">hospitalizations/ED </span>
   <span class="font10">hours </span>
   <span class="font10">including </span>
   <span class="font10">indirect </span>
   <span class="font10">indirectness, </span>
   <span class="font10">interspersed </span>
   <span class="font10">interval </span>
   <span class="font10">intervention </span>
   <span class="font10">investigated </span>
   <span class="font10">length </span>
   <span class="font10">likely </span>
   <span class="font10">medications. </span>
   <span class="font10">members </span>
   <span class="font10">mg/kg/day </span>
   <span class="font10">narrative </span>
   <span class="font10">non‐migraine </span>
   <span class="font10">observed </span>
   <span class="font10">ondansetron </span>
   <span class="font10">overall </span>
   <span class="font10">populations </span>
   <span class="font10">prevalence </span>
   <span class="font10">pt;} </span>
   <span class="font10">receiving </span>
   <span class="font10">regarding </span>
   <span class="font10">reported. </span>
   <span class="font10">resolution </span>
   <span class="font10">riboflavin </span>
   <span class="font10">role </span>
   <span class="font10">satisfaction </span>
   <span class="font10">school </span>
   <span class="font10">size </span>
   <span class="font10">sleeping, </span>
   <span class="font10">slight </span>
   <span class="font10">specified </span>
   <span class="font10">supplements. </span>
   <span class="font10">symptoms) </span>
   <span class="font10">time </span>
   <span class="font10">treat </span>
   <span class="font10">treatment, </span>
   <span class="font10">treatment. </span>
   <span class="font10">trial </span>
   <span class="font10">true </span>
   <span class="font10">twice </span>
   <span class="font10">vomiting; </span>
   <span class="font10">vomits/episode: </span>
   <span class="font10">‐month </span>
  </p>
 </body>
</html>
